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Adamantiades-Behc¸et’s disease is a multisystemic vasculitis with multiorgan involvement. Ocular disorders occur often in this
syndrome typically in the form of a relapsing-remitting panuveitis and vasculitis and can lead to blindness as one of its most
disabling complications if left untreated. There are known risk factors related with the worst visual prognosis, which require
early and intensive treatment in order to obtain a rapid suppression of inflammation and to prevent future relapses. The
management strategy to avoid vision loss and blindness currently involves the use of local and systemic drugs including steroids
and immunosuppressive and biologic agents. This review aims to demonstrate how the introduction and the use of biologic agents
improves the visual outcome of patients with Adamantiades-Behc¸et’s disease.
1. Introduction
Adamantiades-Behc¸et’s disease (ABD) is a chronic, multi-
systemic disorder characterized by recurrent inflammation
that involves multiple organ systems throughout the body.
It has a high prevalence along the ancient “Silk Road,” but
it is an important cause of morbidity throughout the world.
The underlying pathology in ABD is a vasculitis that affects
both the arteries and the veins in all organ systems. The
involvement of major organs can cause permanent damage
and severe complications that may be even life threatening
[1]. Ocular involvement is present in around half of ABD
patients with the percentage varying among 70% in young
men with ABD and 30% in women and elderly patients [1–
3]. Ocular manifestations usually manifest themselves within
5 years from the onset of the disease [2]. Further, bilateral
involvement is frequent and is reported in 75–80% of ABD
patients [2].
The ophthalmic findings described in ABD can involve
either the anterior, posterior, or both segments of the eye
and can be classified as suggested in the review by Ozyazgan
et al. [4] as “reversible changes” or “irreversible changes.”
The reversible changes appear during the activation and
completely disappear after the deactivation of disease; the
irreversible changes develop slowly during the course of
inflammation and do not disappear after remittance. The
most sight-threatening complications often are consequences
of both the reversible and the irreversible modifications to
the anterior or the posterior segment of the eye. Complicated
cataract, macular oedema, secondary glaucoma, epiretinal
membrane, macular hole, and optic disc atrophy may cause
vision loss and, if not treated, also blindness. The risk of
blindness increases progressively reaching 25% at 10 years
and remains constant thereafter [1]. Conventional treat-
ment consists of prednisone, cyclosporine, azathioprine, and
other immunosuppressive agents such as methotrexate and
cyclophosphamide. Steroids are used usually for the rapid
suppression of the inflammation but are quickly tapered
to reduce the risks of secondary cataract and glaucoma.
In patients with severe ocular involvement with vasculitis
and relapses, immunosuppressive agents should be added
to ameliorate the visual prognosis. Nonresponsive patients
can also benefit from biologic agents. Interferon-alpha (INF-
alpha), tumor necrosis factor-alpha (TNF-alpha) antagonists,
and recently interleukin-1 (IL-1) blocking agents have been
used with a significant improvement of visual acuity.
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2. Steroid Treatment and Visual Outcome
In the early 1960s, the treatment of ocular manifestations of
ABD was more dependent upon rheumatologist-prescribed
corticosteroid therapy for extraocular manifestations of this
disease, while corticosteroid monotherapy was the mainstay
of treatment [5]. Currently if the inflammation is located
predominantly in the anterior segment, topical treatment
modalities are recommended together with mydriasis. Dex-
amethasone 0.1%, prednisolone 1%, and fluorometholone
0.1% have been employed topically or through subconjunc-
tival injection (methylprednisolone acetate 20mg) in severe
anterior segment inflammation and for treating hypopyon
[2]. Systemic steroid regime is necessary in case of posterior
segment involvement. Initially, patients are treated with oral
prednisone 1 to 2mg/kg/daily for four days with gradual
tapering of the dose according to the clinical signs [6], or with
high-dose intravenous methylprednisolone [7]. Looking at a
study of the National Eye Institute, comparing three decades
of treatment [8], mean visual acuity was significantly worse
in the 1960s than in the following decades, and accordingly
the mean logarithm of the minimum angle of resolution
(logMAR) score decreased with each decade: respectively,
0.91 logMAR in the 1960s, 0.82 logMAR in the 1980s, and
0.46 logMAR in the 1990s.This could be explained by the fact
that the use of steroids as monotherapy fell significantly from
the 1960s (96%) compared to the 1980s (8%) and the 1990s
(16%) (𝑃 < 0.001). In the 1970s, it was reported that vision
was lost after an average of 3.36 years from the onset of visual
symptoms [9]. Mishima and associates found that more than
50% of the Japanese patients with ABD had a visual acuity of
0.1 decimal or less in 5 years [10].
3. Immunosuppressive Agents and
Visual Outcome
3.1. Cyclosporine A. Cyclosporine A (CSA) is an 11-amino
acid cyclic peptide. It is an alkylating agent that appears to
affect preferentially immunocompetent T-lymphocytes [11].
CSA, in a dose of 5mg/kg/day, was found to be effective
in arresting the inflammatory activity in the eye of patients
with Behc¸et’s disease, resulting in a rapid improvement in
visual acuity.The response rate toCSA inABDpatients varied
between 80 and 91% [12–14]. In a first report published in
1987, visual acuity improved in 12 eyes, was unchanged in
three eyes, and worsened in one eye of patients treated with
CSA [12]. Ozyazgan in a single masked trial demonstrated
that there was an initial improvement in visual acuity with
5mg/kg/day of CSA versus monthly 1 gram of intravenous
bolus of cyclophosphamide. However, this improvement
disappeared during the follow-up time, and at the end of 24
months of observation, visual acuity remained approximately
the same in both groups.
In the cyclophosphamide group, no significant change in
visual acuity occurred; for this reason the author suggested
CSA for short-term use [13].
According to a previous report, Masuda has demon-
strated in a double masked trial that CSA 10mg/kg per day
was effective in treating ocular manifestation of Behc¸et’s
disease and he also observed that the efficacy did not weaken
in long-term treatment [14, 15]. In these patients treated
with CSA, caution is required regarding the potential for
development of hypertension and renal failure.
3.2. Azathioprine. Azathioprine (AZA) is a purine nucleo-
side analogue. Immunologically, it decreases the number of
peripheral T and B lymphocytes and further reduces mixed
lymphocytes reactivity, interleukin-2 synthesis, and IgM pro-
duction [11]. The azathioprine randomized controlled trial
showed that AZA 2.5mg/kg per day was superior to a placebo
in preserving visual acuity in patients with established eye
disease, but there was no evidence that AZA was useful in
restoring compromised vision. It has been suggested also
that AZA can protect against the development of second-
eye disease [16]. According to the previous reports, another
randomized controlled double blind study demonstrated that
blindness and a 2-line drop in the visual acuity of the
right eye occurred significantly more frequently among the
patients originally allocated to the placebo group compared
with patients who originally received AZA, despite posttrial
treatment for patients in both groups when needed [17].
Tugal-Tutkun I described a cohort of 36 childhood-onset
uveitides, treated with oral corticosteroids and immunosup-
pressive treatment if necessary. Twelve patients received AZA
as initial line drugs; looking at final visual acuity, 50% of the
patients showed a visual acuity of 0.6 decimals or better, but
22.7% had a visual acuity of 0.1 decimals and six patients
(16.6%) were legally blind at the time of last visit [18]. In
patients without eye involvement, the use of AZA seems to
prevent the development of new eye disease even during
follow-up and compared with the placebo group blindness
occurred only in 13% of patients, which still remained a high
percentage though [17]. Concomitant use of azathioprine
and/or cyclosporine may improve the outcome.
3.3. Methotrexate. Methotrexate (MTX) is a folic acid ana-
logue and an inhibitor of dihydrofolate reductase, the enzyme
responsible for the conversion of dihydrofolate reductase in
tetrahydrofolate reductase, essential for DNA replication [11].
Davatchi presented the results of a longitudinal study of
up to 15 years, on 682 patients (5447 eye-years of follow-
up) with Behc¸et’s disease and ocular involvement. Patients
were treated with MTX started at 7.5–15mg/week and pred-
nisolone was added at 0.5mg/kg/daily and then adjusted
as needed. At the end of the study, the visual acuity was
improved in 46.5% of the eyes (20% recovered normal vision,
15,3% had useful vision and improved with the treatment,
2,4% were blind and recovered some vision, and 8,4%
recovered at least one eye). In eyes with posterior uveitis,
improvement was achieved in 75.4% of the eyes and in 53.7%
of eyes with retinal vasculitis [19]. Nevertheless, a reduction
of the visual acuity was still observed in 37.2% of eyes. Among
them 4,5% became blind and 5.5% lost their useful vision.
Obviously, the reduction of visual acuity was higher in eyes
with posterior uveitis (11.1%) and retinal vasculitis (30.3%)
[19]. It has been shown also that MTX is potent for anterior
uveitis when used at a low dose of 7.5 to 25mg weekly [20].
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3.4. Cyclophosphamide. Cyclophosphamide is a nitrogen
mustard-alkylating agent, the active metabolites of which are
alkylate purines inDNA andRNA and result in cross-linking,
aberrant base pairing, ring cleavage, and depurination [11]. In
patients, it decreases the number of activated T lymphocytes,
suppresses helper T lymphocytes functions, and decreases
B-lymphocytes for months. Davatchi compared in a double
blind controlled crossover study the short-term efficacy of
pulse cyclophosphamide (PCP) plus prednisolone versus
placebo over prednisolone alone. The mean visual acuity
improved from 3.7 ± 3.2 to 4.9 ± 3.9 (𝑡 = 3.309, 𝑃 < 0.002) in
the PCP group and from 4.4 ± 3.6 to 4.5 ± 3.5 (𝑡 = 0.317, 𝑃 =
0.75) in the placebo group. In the PCP group, VA improved in
57% of the eyes (95% CI: 44–60) and remained stable in 22%
(95% CI: 11–33) but deteriorated in 21% (95% CI: 10–32). In
the placebo group, 45% of the eyes improved (95%CI: 32–58),
14% remained stable (95% CI: 5–23), and 41% deteriorated
(95% CI: 28–54). For this reason, the combination of PCP
and prednisolone is superior compared to prednisolone alone
in maintaining visual acuity [21]. Other parameters such as
disease activity index improved more remarkably in the PCP
group than in the placebo group, but differences were not
statistically significant.
3.5. Biologic Agents. Looking at conventional treatment vis-
ual outcome, there are still high percentages (20–30%) of
patients with a reduction of visual acuity and 10% of patients
becoming blind from posterior eye involvement and uveitis
complications.
In this scenario, biologic agents represent a valid alter-
native for patients nonresponsive to conventional treatments
for achieving a stabilization of visual acuity and avoiding
blindness. Interferon-alpha and TNF-alpha antagonists are
the most frequently used biologic agents; recently, IL-1
blocking agents have been used with satisfactory results in
terms of visual acuity maintenance.
Although the published literature consists of open and
observational studies and while there are not yet available
randomized controlled data on these drugs, the results avail-
able demonstrate a favourable response to biologic agents.
3.6. Interferon-Alpha. Interferons are a group of cytokines
that include interferon-alpha-2a which is used to treat
patients with severe ocular involvement and sight-threat-
ening uveitis entities nonresponsive to conventional immu-
nosuppressive agents. Although there is no controlled data,
open and observational studies have shown the efficacy of
interferon-alpha (IFN-alpha) in controlling uveitis attacks
and reducing relapses [22–29]. However, there is no consen-
sus about the ideal dose and duration of the treatment for
ABD uveitis. For this reason, Onal investigated the long-term
efficacy and safety of low-dose and dose-escalating therapy of
IFN-alpha-2a in the treatment of uveitis in ABD.
This study included 37 patients receiving a daily dose
of 3.0 million IU (MIU) subcutaneously for 14 days. Main-
tenance dose was achieved with 3.0MIU 3 times per week
given subcutaneously. The dosage was increased sequentially
if uveitis relapses occurred. Total therapy duration was 24
months. Improvement in visual acuity was achieved in 41%
of patients with doubling of the visual angle associated with a
decreased rate of uveitis’ relapses [22]. Similar resultswith low
dose of IFN-alpha-2awere obtained byGuedry that described
stabilization or at least an improvement of visual acuity in
87.5% of eyes at two years of treatment [23]. In 2010, Sobaci
presented the results of his prospective study; patients were
treated with INF-alpha-2a 4.5MIU 3 times per week for the
first 3 months, followed by INF-alpha-2a 3MIU for the next
three months. Visual acuity improved in 28.3% of eyes and
was maintained in 76.7% during the follow-up period [24].
Ko¨tter treated patients with an initial higher dose of IFN-
alpha-2a starting with 6MIU subcutaneously daily for at least
14 days and reducing it until discontinuation. Visual acuity
improved in 75.3% (𝑛 = 55) of eyes, remained stable in 22%
(𝑛 = 16) of eyes, and worsened in 2.7% (𝑛 = 2) of eyes. The
increase of visual acuity for the right eyes was 0.33, and for
the left eyes 0.36 logMAR. In 7 eyes, the final visual acuity
was inferior to 0.1 logMARbut remained unchanged from the
beginning [25, 26]. Ko¨tter obtained a response rate of 92% in
a relatively short time of 2 to 4 weeks, and discontinuation
of the treatment was possible in 40% of patients. After 5
years of follow-up in patients treated with IFN 2-alpha, 67%
of eyes obtained an increase of two lines or more in visual
acuity [27]. Similar results were obtained by Deuter with an
improvement or at leastmaintenance of visual acuity in 94.8%
of eyes treated with a dose of 6MIU subcutaneously daily for
at least 14 days that is then tapered to a maintenance dosage
of 3 million IU twice per week and finally discontinued,
if possible. Median visual acuity was 0.30 logMAR at the
beginning and improved to 0.07 logMAR at the end of follow-
up period. Only 12.5% of eyes had a final visual acuity of
1.0 logMAR or less, due to preexisting irreversible ocular
damage [28]. Tugal-Tutkun I. observed in her retrospective
analysis between September 2001 and May 2005 similar
results in terms of visual acuity recovery. As a matter of fact,
the best visual acuity was achieved after amedian of 4months
of IFN-alpha therapy andwas found to be 0.28±0.34 logMAR
units in the right eye and 0.45 ± 0.56 logMAR units in the
left eye. The best level of visual acuity achieved by IFN-alpha
therapy was preserved throughout follow-up in 95% patients
[29]. In her series of patients, only 36.4% of patients remained
relapse-free, and complete remission was achieved only in
20% of patients compared with the data reported by Ko¨tter
where 82% of patients were relapse-free and 40% of patients
achieved complete remission [26]. Patients treated with IFN-
alpha often experienced a flu-like syndrome, weight loss, and
often depression. For these reasons, the use of this drug is
quite limited.
The main advantage of IFN-alpha treatment seems to be
the possibility of discontinuation of treatmentwithout relapse
in at least 50% of patients and the preservation of visual
acuity in almost 90% of patients compared with standard
immunosuppressive therapy and even when compared with
anti-TNF [30]. However, as assessed by Bodaghi and col-
leagues [31], the efficiency of IFN-alpha in sight-threatening
uveitis seems to act more to suspend rather than to cure and
for this reason it may be proposed as a second-line therapy
after failure of conventional immunosuppressive treatments
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in nonresponsive patients. In thisway, nonresponsive patients
could avoid sight-threatening complications and blindness.
3.7. TNF-Alpha Antagonists. Tumor necrosis factor-alpha is
a pleiotropic cytokine that has been shown to be elevated in
patients with Behc¸et’s disease and other autoimmune dis-
eases. Numerous cells, also lymphocytes, produce TNF-
alpha and their targets are two receptors known as p55
(TNF-R1) and p75 (TNF-R2). When TNF-alpha is produced
during inflammation, it activates T-cells and macrophages
and determines upregulation and expression of endothelial
adhesion molecules and proinflammatory cytokines [32].
The first available molecule targeting TNF-alpha was a
chimeric IgG monoclonal antibody infliximab (Remicade,
Schering-Plough Pharma Inc.); later etanercept (Enbrel,
White Pharmaceuticals Inc.), a p75 TNF-alpha receptor
fusion protein, was developed.The last anti-TNF-alpha agent
produced was adalimumab (Humira, Abbott Pharmaceuti-
cals Inc.), a recombinant human IgG1 monoclonal antibody
[32].
3.8. Infliximab. Infliximab infusion, used at a dose of 5mg/kg
every 6–8 weeks, is demonstrated to be effective in reduc-
ing ocular relapses and maintaining visual acuity [33–41].
Sfikakis described in a case series the effect of infliximab in 5
patients treated with standard immunosuppressive therapies.
He observed a rapid and effective suppression of the ocular
inflammation in these patients after seven days, confirmed
also by an improvement and stabilization in visual acuity in
all cases during the follow-up time [33]. These preliminary
observations were confirmed also by Ohno and colleagues
that described a significant reduction in the frequency of
uveitis attacks during the efficacy-evaluation period of their
study, and an improvement in visual acuity was noted in eyes
in which uveitis remained in remission [34].The visual acuity
improvement obtained with the infusion of the anti-TNF-
alpha agents could reach the sixth line of visual acuity as
reported by Bodaghi and colleagues. This was a retrospective
study of 12 patients (21 eyes) followed for a mean of 17.4
months (range: 8–30) [35]. Tugal-Tutkun described the long-
term results of infliximab infusions of 5mg/kg administered
at weeks 0, 2, 6, and 14 and the patients were observed since
enrolment for 54 weeks. The visual acuity improved signif-
icantly during the infusion period (weeks 0–22) but then
decreased during the observational period (23–54 weeks).
This was explained by the authors both for the frequency of
uveitis attacks and for the need of corticosteroids treatment
after the initial beneficial effects of infliximab infusions. For
these reasons, treatment with anti-TNF-alpha agents should
be continued in order to maintain the beneficial effects in
cases of nonresponsive uveitis [36]. In a review paper in
April 2007, Sfikakis et al. suggested that infliximab was the
best available treatment in acute sight-threatening ocular
inflammation in patients affected by Behc¸et’s disease and
should be used alone or as an add-on therapy in selected cases
[37].
Compared with corticosteroids, high-dose methylpred-
nisolone intravenously (1 g/day for 3 days), or intravitreal
triamcinolone acetonide (4mg) at the attack’s onset, inflix-
imab was equally effective in improving visual acuity from
baseline but with less complications such as cataract or glau-
coma and with a faster effect [38]. Yamada retrospectively
compared the efficacy of infliximab versusCSAanddescribed
an improvement of visual acuity in 97% of eyes treated with
infliximab versus the 93% of patients treated with CSA; the
difference was not statistically significant. Nevertheless the
study demonstrated that infliximab was more effective than
CSA in the first 6 months [39]. Beside the rapid effect of
action, a multicenter prospective study showed that uveore-
tinitis improved in 92% accompanied by visual acuity that
improved from 0.736 logMAR at the first infliximab infusion
to 0.616 logMAR after 1 year and remained unchanged in the
other patients. Infliximab also decreased the frequency of
recurrence and 44% of patients were attack-free after twelve
months [40]. In addition, other studies demonstrated the
efficacy of infliximab in improving visual acuity by reducing
optic disc neovascularization and background retinal vascu-
lar leakage, as demonstrated with fluorescein angiography.
The best corrected visual acuity was maintained or improved
in 92.8% of eyes at 12months, and in 80% of eyes at 24months
[41].
Finally we can conclude that almost all patients treated
with infliximab, alone or as an add-on therapy, were non-
responsive to conventional treatments and achieved a fast
suppression of the acute ocular inflammation. Less data is
available on long-term outcomes, since it is also well known
that the development of human antichimera antibodies
(HACAs) has been implicated in the observed decline in
therapeutic response to infliximab. The use of infliximab, as
other anti-TNF-alpha agents, is not totally safe; Neri et al. in
2004 reported about the reactivation of tuberculosis under
infliximab in a patient withABD; remember that the endemic
areas for ABD are also endemic for tuberculosis [32].
3.9. Etanercept. Etanercept is a recombinant human p75
TNF-alpha receptor artificial fusion protein; in a double-
blind, placebo-controlled study of 40male patientswithABD,
Melikoglu et al. [42] reported that etanercept (25mg twice/
week, for 4 weeks) was effective in suppressing most muco-
cutaneous lesions in Behc¸et’s patients. Etanercept was also
given to treat children with ABD-associated uveitis at a dose
of 0.4–0.5mg/kg administered twice weekly as subcutaneous
injections. At study entry, 39/42 eyes had active uveitis with
normal visual acuity in 59% of eyes, impaired visual acuity
in 10% of the eyes, and legal blindness in 31% of the eyes.
Legal blindness was bilateral in 14% of the eyes. Ten of the
21 patients (48%), with 19 affected eyes, had normal best cor-
rected visual acuity in both eyes.The causes of legal blindness
were cataract, cystoid macular edema, and retinal detach-
ment. Patients were treatedwith etanercept or infliximab, and
at the end of the study best corrected visual acuity improved
in 5/11 patients (7/16 eyes, 43%). Four patients (5/16 eyes, 31%)
improved as a result of cataract surgery. In two eyes (two
patients, both on infliximab), improvement of visual acuity
from 20/400 to 20/70 and from 20/400 to 20/20, respectively,
was unrelated to cataract surgery. Vision decreased in 2/18
patients (2/27 eyes, 7%) from 20/100 to 20/200 and from
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20/60 to 20/200, respectively, both on etanercept (13% of
etanercept treated eyes) due to uncontrolled inflammation,
and remained unchanged in 16 patients (25 eyes) during the
study (difference between etanercept and infliximab treated
group, 𝑃 = 0.48). The difference in improvement of visual
acuity between etanercept and infliximab treated patients was
not statistically significant; however, the authors concluded
at the end of the paper that infliximab seemed superior to
etanercept not only because of decreasing the number of
concomitant medications required to control the uveitis, but
also due to a lower rate of new-onset glaucoma and cataract
[43].
In conclusion, we can consider the soluble TNF receptor
as an alternative for nonresponsive patients to the other anti-
TNF-alpha agents.
3.10. Adalimumab. Adalimumab is a recombinant human
IgG1 monoclonal antibody targeting the TNF-𝛼; it also binds
soluble and the membrane-bound form of TNF-𝛼 [32].
Adalimumab, as previous biologic agents, has been used to
treat nonresponsive ocular Behc¸et syndrome as it has some
advantages: first of all, the self-administration and then a
lower risk of anti-drug antibody formation. In 2007, there
was a first case series describing the effect of adalimumab
in sight-threatening uveitis; in all three patients treated, the
visual acuity remained stable; and in two eyes of two different
patients, an improvement also has been observed [44]. In
2010, Bawazeer et al. described the improvement of visual
acuity and the corticosteroid and immunosuppressive spar-
ing effect of adalimumab in 11 patients with ocular Behc¸et’s
disease. Adalimumab was administered subcutaneously at
a dose of 40mg every 2 weeks; of the 21 eyes, 17 had an
improvement of visual acuity by 4.3 (range: 0–8) lines; 4
eyes of 3 patients did not improve in visual acuity [45].
Takase et al. reported their experience describing the suc-
cessful switching from infliximab to adalimumab in ABD
patients. Changing to adalimumab induced clinical remission
again, thus suggesting that adalimumab can be an effective
alternative to infliximab for patients having a hypersensitivity
to this drug [46]. The application of adalimumab can also
be hypothesized beside nonresponsive uveitis in panuveitis
and pediatric uveitis [47, 48]. Unfortunately, adalimumab
treatment is not totally safe, as multiple side effects have been
reported recently such as reactivation of latent tuberculosis,
endogenous endophthalmitis, retrobulbar neuritis, bilateral
optic neuropathy, precipitation of systemic lupus erythemato-
sus, secondary malignancies, lymphoma, and cardiac failures
[32].
Although the results provided in ABD can be promising,
no controlled trial is available and it is not possible to compare
the characteristics of different anti-TNF-𝛼, so that they are
limited to nonresponsive cases of the disease.
3.11. IL-1 Blocking Agents. IL-1-blocking agents have started
to be used recently in sight-threatening and nonresponsive
cases. A small study on 7 patients treated with a single infu-
sion of XOMA 052 (gevokizumab) 0.3mg/kg demonstrated
a rapid and meaningful improvement of the visual acuity
starting from day 1, except in two patients; resolution of
the ocular inflammation was observed in 5 patients at day 28;
and all these 5 patients remained attack-free for a median of
49 days. XOMA 052 was well tolerated and no drug-related
adverse events were observed [49]. Another recombinant
form of human IL-1 receptor antagonist is anakinra, which
is approved for the treatment of Rheumatoid Arthritis in
combination with methotrexate. Emmi et al. described the
use of this drug in a patient with ABD and serious ocular
involvement. The patient was treated with anakinra at a dose
of 100mg/day and after three months from the beginning
of the treatment, ocular inflammation had disappeared and
visual acuity from 20/50 in RE and 20/32 in LE was restored
to 20/20 in both eyes [50]. Ugurlu published the favourable
results obtained with canakinumab, another IL-1 receptor
antagonist, treating a 16-year-old femalewithABDandocular
involvement nonresponsive to other immunosuppressives.
The young patient treated with a single dose of 150mg of
canakinumab obtained a resolution of the ocular inflam-
mation in the right eye with a visual acuity of 0.4. The
left eye was not evaluated because of the presence of a
complicated cataract. The patient remained free of attacks
during the 8 weeks of follow-up. Interestingly, this patient
was nonresponsive to anakinra but obtained a remission
of the ocular inflammation with canakinumab. Both agents
are IL-1 blockers but may act in different ways and have
different half-lives. While anakinra blocks both IL-1𝛼 and IL-
1𝛽, canakinumab specifically targets IL-1𝛽. It was also noticed
that, after the infusion of IL-1 blocking agents, the circulating
white blood cells developed a less inflammatory phenotype
compared with baseline [51].
Although these studies have limitations resulting from
their design and the small number of patients, the results do
support additional studies to evaluate the role of IL-1 blocking
agents for the treatment of uveitis and retinal vasculitis and
for nonocular ABD manifestations as well as other types of
noninfectious inflammatory uveitis.
4. Changes in the Course of
the Disease Over Time
ABD is a rare disease but has a relatively high prevalence
along the ancient “Silk Road.” Since 1950 until the present,
the medical treatments options have been evolving to obtain
a better control of the inflammation, a reduction of the sight-
threatening complications, and a better final visual outcome.
The first drugs introduced to manage this syndrome
were steroids, followed then by immunosuppressive agents
(alkylating agents, nucleoside analogues, folic acid analogues,
and nitrogen mustard-alkylating agents) and finally biologic
agents (INF-𝛼 and TNF-𝛼 antagonists and IL-1 blocking
agents).
In a large series from Turkey, including patients seen
between 1980 and 1998, initial visual acuity was 0.1 or less
in 647/1567 eyes (41.2%) [1]. A recent multicenter Turkish
study conducted in 2004 showed that a lower percentage
(21.7%) of eyes with Behc¸et’s uveitis had initial visual acuity
of 0.1 or less, suggesting a trend toward a milder disease
[52]. Cingu et al., who compared patients who presented
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in the period 2000–2004 with those who had presented a
decade earlier, have confirmed this tendency also.The authors
found a better initial, potential, and 3-year visual acuity in
patients from the 2000s period and none of the patients
became legally blind during the 3 years of follow-up in this
group. This may be explained by a milder disease in this
period and/or more frequent use of immunomodulatory
treatment before referral [53]. Disease severity and visual
outcomes of patients with ABD uveitis over the decades have
been changing significantly also in other countries. In Japan,
Yoshida A. et al. described between the 1980s and 1990s
an increase in the percentage of eyes with good visual acuity
(≥20/30) and a significant reduction in eyes with poor
visual acuity (≤20/200); and they justified this change as a
result of improvements in environmental factors (e.g., puta-
tive microorganisms, lifestyles, and hygienic situations) [54].
Similar to trends reported from Japan, Khairallah and asso-
ciates found that Tunisian patients with ABD uveitis who
presented after 2001 had a better final visual acuity than
those who presented before 2001. Only 3.4% of patients
suffered from blindness and 12.5% suffered from unilateral
blindness. The authors justify this trend due to the use of
immunomodulatory drugs as first-line therapy after 2001 but
a milder disease could not be excluded because initial visual
acuity was also better in the more recent study period [55].
The study by Kump and associates in the United States has
shown a similar trend in a nonendemic population; mean
visual acuity in the 1990s group was significantly better than
in the previous decades (𝑃 < 0.001 for the 1960s group
and 𝑃 = 0.019 for the 1980s group) and it seems that
newer immunomodulating and biologic agents may offer an
improved prognosis in patients with ABD [8].
In a recent paper, Taylor reported improved visual prog-
nosis in patients with ABD who presented at two referral
centres in England and in Australia between 2000 and 2010.
They estimated the risk of visual loss to be 39% and the
risk of severe visual loss to be 24% at 10 years. Male sex,
unilateral disease, and left eye involvement increased the
risks of severe visual loss at 5 and 10 years in this series of
patients. Patients who were treated with anti-TNF-𝛼 were
less likely to have severe visual loss, respectively, at 5 and
10 years. Taken together, these results suggest that adequate
immunosuppression can reduce the risk of severe visual
loss in patients with ocular ABD but that azathioprine is
not effective enough to achieve this goal [56]. Krause and
associates in Berlin analyzed retrospectively the data of 140
patients with ABD and found that the risk of losing useful
vision was 21% [57], less than 75% of Benezra and Cohen’s
study [6] and 72% less than described in another study
published in 1995 inGermany [58].Mean andmedian Snellen
visual acuities were reported to be 0.3 and 0.6 at baseline and
0.4 and 0.8 after 3 years, respectively [57]. In Switzerland,
another nonendemic country, mean Snellen visual acuity
was 0.74 at baseline and 0.79 after a mean follow-up of 5.7
years [59]. ABD appears to be less severe in this area, but in
presence of ocular clinical and angiographic involvement, the
authors decided to treat patients even if the visual acuity was
good; and the final visual outcome justified this aggressive
treatment. In a recent study from China in a single center,
which included 437 Behc¸et’s disease patients seen between
1995 and 2006, final visual acuity was less than 0.1 in 20.4% of
eyes after a median follow-up of 4 years [60].
Muhaya and associates compared Behc¸et patients seen
in Japan and the United Kingdom in a cross-sectional
observational study conducted simultaneously at two centres.
The duration of ocular disease was around 7 years in both
cohorts. Even if the treatment schedules were very different
and Japanese patients had more active disease, the visual
results were comparable. Visual acuity was worse than 6/60
in 31% of patients in Japan and 21% of patients in the United
Kingdom; oral steroids and azathioprine are widely used
in London; on the contrary, colchicine was used instead
in Japan. This cross-sectional study reveals differences in
the clinical features and management of ocular disease in
ABD patients, but this had no significant effect on the visual
outcome at seven years [61].
5. Conclusion
In conclusion, in order to restore and maintain good visual
acuity in ABD with ocular involvement, the importance of
the early use of combined immunomodulatory regimens and
use of biologic agents seems clear.This is muchmore effective
in nonresponsive cases where the reduced severity and
number of uveitis attacks can prevent early visual loss [62].
The evidence-based European League Against Rheumatism
(EULAR) recommendations for the management of ABD,
published in 2008 and still valid, suggest for posterior eye
involvement a treatment regimen that includes systemic
steroids and azathioprine [63]. Corticosteroids rapidly sup-
press the inflammation but potential side effects, including
cataracts and glaucoma, cause concern. Azathioprine is
widely accepted as the initial agent for ocular involvement of
ABD. The EULAR committee discussed also a possible role
of azathioprine as a prophylactic treatment in patients with
ABD at high risk of developing eye involvement; but it was
decided that more prospective data were needed.
In case of severe eye involvement, identified as a drop of
two lines or more in visual acuity on a 10/10 scale and/or
retinal disease (retinal vasculitis or macular involvement),
another immunosuppressive needs to be added. Particularly,
it is recommended that either cyclosporine A or TNF-alpha
antagonists such as infliximab may be used in combination
with azathioprine and corticosteroids; alternatively, INF-
alpha with or without corticosteroids could be used.
Due caution for hypertension and nephrotoxicity is
important when using cyclosporine A; instead reactivation
of tuberculosis has to be considered when using TNF-
alpha antagonists. IFN-alpha, alone or in combination with
corticosteroids, appears to be a second choice in eye disease
due to financial and safety concerns, mainly depression
and cytopenias [63]. Recently, IL-1 blocking agents have
been used in sight-threatening and nonresponsive cases with
preliminary good results [49–51].
Another important issue to consider when using immu-
nomodulatory drugs and biologic agents is the switching
effect in the event of failure of desired response to one bio-
logic therapy [64]; the efficacy of changing from a biologic
BioMed Research International 7
agent to another one suggests changing the drugs either for
poor response (primary failure) or for progressive decrease
of efficacy because of the production of patient antibody
reaction to the nonhuman part of the chimericmolecule used
for treatment (secondary failure).
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